NASDAQ · BDRX
Biodexa Pharmaceuticals Plc
Healthcare · Biotechnology
$1.33
Up+$0.21 (+18.75%)
Updated Sep 16, 2026, 6:30 AM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 4.12M
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- $0.60 – $11.88
- Volume
- 54.69M
- Avg. volume
- 695.79K
Price performance
BDRX price history
1M range · 20 trading sessions · Daily adjusted prices
BDRX closed at $1.33 after 20 trading sessions, down 4.32% for the selected period.
- Last close
- $1.33
- Period change
- -4.32%
- Period low
- $0.66
- Period high
- $1.39
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $1.29 | $1.43 | $1.13 | $1.33 | 54.69M |
| Sep 14, 2026 | $1.29 | $1.46 | $1.10 | $1.12 | 6.16M |
| Sep 11, 2026 | $0.88 | $1.5499 | $0.8342 | $1.30 | 142.44M |
| Sep 10, 2026 | $0.7998 | $0.845 | $0.61 | $0.6601 | 202.08K |
| Sep 9, 2026 | $0.8441 | $0.8441 | $0.79 | $0.8122 | 101.77K |
| Sep 8, 2026 | $0.82 | $0.8999 | $0.82 | $0.8308 | 95.25K |
| Sep 4, 2026 | $0.7838 | $0.86 | $0.7731 | $0.848 | 105.07K |
| Sep 3, 2026 | $0.771 | $0.7988 | $0.7623 | $0.7984 | 99.61K |
| Sep 2, 2026 | $0.758 | $0.80 | $0.7553 | $0.7849 | 58.77K |
| Sep 1, 2026 | $0.79 | $0.81 | $0.7802 | $0.7808 | 82.69K |
| Aug 31, 2026 | $0.8576 | $0.8576 | $0.78 | $0.8117 | 114.31K |
| Aug 28, 2026 | $0.87 | $0.88 | $0.8303 | $0.8681 | 110.16K |
| Aug 27, 2026 | $0.96 | $0.96 | $0.8609 | $0.90 | 280.16K |
| Aug 26, 2026 | $1.07 | $1.08 | $0.93 | $0.9773 | 1.07M |
| Aug 25, 2026 | $1.455 | $1.51 | $1.15 | $1.18 | 16.61M |
| Aug 24, 2026 | $1.22 | $1.35 | $1.18 | $1.20 | 39.53K |
| Aug 21, 2026 | $1.28 | $1.32 | $1.215 | $1.27 | 56.09K |
| Aug 20, 2026 | $1.28 | $1.3499 | $1.1701 | $1.26 | 73.26K |
| Aug 19, 2026 | $1.36 | $1.5255 | $1.25 | $1.26 | 1.21M |
| Aug 18, 2026 | $1.43 | $1.5178 | $1.34 | $1.39 | 16.72K |
Latest BDRX news
The latest Smart Investors Daily articles mentioning BDRX.
Stock researchCompany · Overview
BDRX research
Overview
Company profile and research snapshot.
Company profile
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $183.60
- Implied upside
- —
- Analysts
- 7
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 8, 2024 | Ladenburg Thalmann | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.
